Table 2 CT and laboratory characteristics of patients with COVID-19 at admission
All patients (n = 53) | ^Wuhan (n = 30) | ^Non-Wuhan (n = 23) | p value | |
|---|---|---|---|---|
Chest CT: No., (%) | ||||
Ground-glass opacity | 46/53 (86.8%) | 28/30 (93.3%) | 18/23 (78.3%) | 0.231|| |
Patchy shadowing | 27/53 (50.9%) | 14/30 (46.7%) | 13/23 (56.5%) | 0.477|| |
Consolidation | 7/53 (13.2%) | 3/30 (10%) | 4/23 (17.4%) | 0.705|| |
Subpleural | 47/53 (88.7%) | 26/30 (86.7%) | 21/23 (91.3%) | 0.928|| |
CT score of lung involvement | ||||
Median (IQR) | 4.0 (3.0–6.0) | 4.0 (3.8–6.0) | 3.00 (2.0–5.0) | 0.322‡‡ |
Laboratory findings Mean (SD) or Median (IQR) | ||||
White blood cell, NR: 3.5–9.5 × 109/L | 4.01 (3.46–4.76) | 3.98 (3.17–5.05) | 4.02 (3.54–4.65) | 0.753‡‡ |
Lymphocyte, NR: 1.1–3.2 × 109/L | 1.13 (0.49) | 1.08 (0.48) | 1.19 (0.51) | 0.418‡ |
Lymphocyte percent, NR: 20–50% | 28.4 (12.3) | 27.9 (12.2) | 29.1 (12.7) | 0.731‡ |
Neutrophil, NR: 1.8–6.3 × 109/L | 2.30 (1.79–2.98) | 2.15 (1.75–2.93) | 2.42 (2.02–3.11) | 0.490‡‡ |
Neutrophil percent, NR: 40–75% | 60.5 (13.1) | 60.5 (13.1) | 60.5 (13.5) | 0.991‡ |
C-reactive protein, NR < 3 mg/L | 13.7 (4.1–30.0) | 15.0 (8.4–24.8) | 13.7 (2.0–51.1) | 0.809‡‡ |
Procalcitonin, NR < 0.1 ng/mL | 0.11 (0.10–0.12) | 0.11 (0.10–0.12) | 0.11 (0.10–0.12) | 0.372‡‡ |
Alanine aminotransferase, NR: 9–50 U/L | 28.0 (20.0–49.0) | 28.5 (19.8–45.5) | 28.0 (23.0–51.0) | 0.548‡‡ |
Aspartate aminotransferase, NR: 15–40 U/L | 28.0 (22.0–39.0) | 28.0 (22.0–35.0) | 29.0 (19.0–42.0) | 0.986‡‡ |
Albumin, NR: 40-55 g/L | 36.7 (3.7) | 36.2 (3.2) | 37.3 (4.3) | 0.304‡ |
Globulin, NR: 20-40 g/L | 36.4 (33.0–40.0) | 36.3 (33.0–41.4) | 36.5 (33.0–38.3) | 0.554‡‡ |
Albumin / globulin ratio, NR: 1.2–2.4 | 1.02 (0.20) | 0.99 (0.19) | 1.06 (0.21) | 0.226‡ |
Glomerular filtration rate, NR > 90 ml/min/1.73m2 | 104.3 (93.7–112.9) | 100.1 (92.5–109.0) | 108.6 (93.6–117.1) | 0.170‡‡ |
Creatine kinase, NR: 50–310 U/L | 61.0 (42.0–116.0) | 59.0 (39.0–99.5) | 70.0 (45.0–134.0) | 0.206‡‡ |